These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 36306594)

  • 1. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.
    Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K
    Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated.
    Mortezaee K; Majidpoor J
    J Cell Mol Med; 2023 Feb; 27(3):311-321. PubMed ID: 36625080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.
    Kong X; Peng H; Liu P; Fu X; Wang N; Zhang D
    Cancer Sci; 2023 Jun; 114(6):2265-2276. PubMed ID: 36751987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
    Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
    Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer stem cells (CSCs) in cancer progression and therapy.
    Najafi M; Farhood B; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy - Updated.
    Karami Z; Mortezaee K; Majidpoor J
    Int Immunopharmacol; 2023 Sep; 122():110648. PubMed ID: 37459782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.
    Cao L; Bridle KR; Shrestha R; Prithviraj P; Crawford DHG; Jayachandran A
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
    Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
    Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
    Shrestha R; Bridle KR; Cao L; Crawford DHG; Jayachandran A
    Curr Oncol; 2021 Jun; 28(3):2150-2172. PubMed ID: 34208001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
    Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem cell-derived exosomes in CD8
    Gholami A
    Int Immunopharmacol; 2024 Aug; 137():112509. PubMed ID: 38889509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.
    Hsu JM; Xia W; Hsu YH; Chan LC; Yu WH; Cha JH; Chen CT; Liao HW; Kuo CW; Khoo KH; Hsu JL; Li CW; Lim SO; Chang SS; Chen YC; Ren GX; Hung MC
    Nat Commun; 2018 May; 9(1):1908. PubMed ID: 29765039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
    Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
    Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.
    Messeha SS; Zarmouh NO; Soliman KFA
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.
    Wu T; Tang C; Tao R; Yong X; Jiang Q; Feng C
    Front Immunol; 2021; 12():693881. PubMed ID: 34552581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy.
    Mortezaee K; Majidpoor J; Kharazinejad E
    Biomed Pharmacother; 2023 Jun; 162():114646. PubMed ID: 37011483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
    Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
    Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
    Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
    J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.